Authors: Shrestha, Umid K.; Jha, Rakesh K.u.m.a.r.; Xia, Bing

Source: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Cu, Volume 8, Number 3, September 2009 , pp. 270-278(9)

Publisher: Bentham Science Publishers

Abstract:

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain and symptoms of arthritis and soft tissue inflammation. The gastrointestinal (GI) adverse effects such as gastric and duodenal ulcers and their complications are the major limitations to the prescription of these drugs. As many as 25% of chronic NSAID users develop peptic ulcer disease among which 2%-4% bleed or perforate. Hence, the emphasis has always been on developing novel NSAIDs without GI toxicity. Selective cyclooxygenase (COX)-2 inhibitors (coxibs) elicit less clinically significant GI damage and bleeding than conventional NSAIDs, but there are concerns about the cardiovascular safety of these drugs. New treatment modalities such as Nitric Oxide (NO) releasing NSAIDs, dual COX/5-lipooxygenase (5-LOX) inhibitors and selective inhibition of terminal Prostaglandin synthases may be superior to coxibs in terms of reducing toxicity and increasing potency and efficacy. The advent of new mediators (lipoxins, Hydrogen Sulfide) may offer new key targets for safer NSAIDs. Several Phosphatidylcholine (PC)-NSAIDs, which were found to have increased analgesic and antiinflammatory activity with significantly less gastric and intestinal damage in animal models, are now in the advanced clinical trial. The R-enantiomers of NSAIDs, which may be helpful in chemoprevention of cancer and Alzheimer's disease, generally exhibit greatly reduced GI toxicity. The evolution of these different novel NSAIDs may provide new modalities of anti-inflammatory therapies with greatly reduced GI toxicity.

Keywords: Non-steroidal anti-inflammatory drug; gastrointestinal toxicity; COX-2 inhibitor; COX/5-LOX inhibitor; NO releasing NSAID

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187152309789152011

Publication date: 2009-09-01

More about this publication?

• Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Anti-Inflammatory & Anti-Allergy Agents.
  
  Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Anti-Inflammatory & Anti-Allergy Medicinal Chemistry.
  
  Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Anti-Inflammatory & Anti-Allergy Agents drug discovery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Shrestha, Umid K. ;  Jha, Rakesh K.u.m.a.r. ;  Xia, Bing

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers